Continuous Engagement of a Self-specific Activation Receptor Induces NK Cell Tolerance
Overview
General Medicine
Authors
Affiliations
Natural killer (NK) cell tolerance mechanisms are incompletely understood. One possibility is that they possess self-specific activation receptors that result in hyporesponsiveness unless modulated by self-major histocompatability complex (MHC)-specific inhibitory receptors. As putative self-specific activation receptors have not been well characterized, we studied a transgenic C57BL/6 mouse that ubiquitously expresses m157 (m157-Tg), which is the murine cytomegalovirus (MCMV)-encoded ligand for the Ly49H NK cell activation receptor. The transgenic mice were more susceptible to MCMV infection and were unable to reject m157-Tg bone marrow, suggesting defects in Ly49H(+) NK cells. There was a reversible hyporesponsiveness of Ly49H(+) NK cells that extended to Ly49H-independent stimuli. Continuous Ly49H-m157 interaction was necessary for the functional defects. Interestingly, functional defects occurred when mature wild-type NK cells were adoptively transferred to m157-Tg mice, suggesting that mature NK cells may acquire hyporesponsiveness. Importantly, NK cell tolerance caused by Ly49H-m157 interaction was similar in NK cells regardless of expression of Ly49C, an inhibitory receptor specific for a self-MHC allele in C57BL/6 mice. Thus, engagement of self-specific activation receptors in vivo induces an NK cell tolerance effect that is not affected by self-MHC-specific inhibitory receptors.
Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity.
Sabag B, Puthenveetil A, Levy M, Joseph N, Doniger T, Yaron O EMBO J. 2024; 43(13):2552-2581.
PMID: 38637625 PMC: 11217363. DOI: 10.1038/s44318-024-00094-5.
An inference model gives insights into innate immune adaptation and repertoire diversity.
Qin Y, Mace E, Barton J Proc Natl Acad Sci U S A. 2023; 120(38):e2305859120.
PMID: 37695895 PMC: 10515141. DOI: 10.1073/pnas.2305859120.
Manjili M J Immunol. 2023; 210(5):521-530.
PMID: 36881868 PMC: 10000300. DOI: 10.4049/jimmunol.2200672.
Progress in xenotransplantation: overcoming immune barriers.
Sykes M, Sachs D Nat Rev Nephrol. 2022; 18(12):745-761.
PMID: 36198911 PMC: 9671854. DOI: 10.1038/s41581-022-00624-6.
Cronk J, Dziewulska K, Puchalski P, Crittenden R, Hammarskjold M, Brown M J Immunol. 2022; 209(8):1545-1554.
PMID: 36165178 PMC: 9529956. DOI: 10.4049/jimmunol.2200441.